Drug intelligence / Profile preview

placebo

Development stage: Unknown
Lead developer: Novartis
Administration: Inhalation

Overview

Placebo is an inactive substance or treatment designed to have no therapeutic effect. In clinical trials, a placebo is used as a control to compare against the effects of an active drug—in this case, indacaterol. Placebos are typically formulated to resemble the active drug in appearance and administration but do not contain any pharmacologically active ingredients. They are essential for assessing the efficacy and safety of new treatments by providing a baseline for comparison. Indacaterol is a long-acting beta-2 adrenergic agonist (LABA) used as an inhaled bronchodilator for chronic obstructive pulmonary disease (COPD), but "placebo to indacaterol" refers specifically to the use of a placebo in studies evaluating indacaterol[8].

Other names: placebo to indacaterolplacebo

Beyond the preview

Go deeper on placebo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on placebo.

Explore the full profile